Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea® Compared to Eylea® Monotherapy

NCT04200248 is registered in ClinicalTrials.gov with Ribomic USA Inc as lead sponsor.

NCT NCT04200248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04200248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea® Compared to Eylea® Monotherapy
Lead sponsor
Ribomic USA Inc
Phase
Phase 2
Overall status
Completed
Start date
December 2, 2019
Completion date
December 22, 2021
Enrollment
94 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

exudative age-related macular degeneration